Opinion|Videos|October 28, 2024
Current Approach to Treating Anemia in LR-MDS
Author(s)Saeed Sadeghi, MD
Saeed Sadeghi, MD, shares his current approach to treating anemia in lower-risk myelodysplastic syndromes (LR-MDS), detailing when to choose erythropoiesis-stimulating agents (ESAs) for first-line treatment, conditions for switching therapies, and factors influencing the decision to use luspatercept as a first-line option, including considerations for dose escalation.
Episodes in this series
Video content above is prompted by the following:
What is your current approach for treating anemia in LR-MDS?
- When would you choose ESAs for first-line treatment?
- When would you switch therapies? Would you dose escalate before switching to an EMA (eg, second line)?
- What factors lead to a decision to use luspatercept as a first-line treatment?
- When do you dose escalate?
